Alkermes PLC (NASDAQ:ALKS) Director Paul J. Mitchell sold 1,500 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $50.64, for a total value of $75,960.00. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Alkermes PLC (NASDAQ ALKS) opened at 50.29 on Monday. The stock’s 50 day moving average price is $51.08 and its 200-day moving average price is $55.51. The company’s market capitalization is $7.73 billion. Alkermes PLC has a 12 month low of $41.93 and a 12 month high of $63.40.
Alkermes PLC (NASDAQ:ALKS) last released its earnings results on Thursday, July 27th. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.02. Alkermes PLC had a negative return on equity of 9.12% and a negative net margin of 24.33%. The company had revenue of $218.80 million during the quarter, compared to analyst estimates of $216.54 million. During the same quarter in the previous year, the company posted ($0.01) EPS. Alkermes PLC’s revenue for the quarter was up 12.1% on a year-over-year basis. On average, equities research analysts predict that Alkermes PLC will post ($0.04) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by BBNS and is the property of of BBNS. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/insider-selling-alkermes-plc-alks-director-sells-75960-00-in-stock/1694921.html.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALKS. Greenwood Capital Associates LLC raised its position in Alkermes PLC by 1.1% during the 2nd quarter. Greenwood Capital Associates LLC now owns 3,770 shares of the company’s stock valued at $219,000 after purchasing an additional 41 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Alkermes PLC by 0.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 7,104 shares of the company’s stock valued at $415,000 after purchasing an additional 42 shares during the last quarter. World Asset Management Inc grew its holdings in shares of Alkermes PLC by 1.9% during the 2nd quarter. World Asset Management Inc now owns 6,939 shares of the company’s stock worth $402,000 after acquiring an additional 128 shares during the period. Capstone Asset Management Co. grew its holdings in shares of Alkermes PLC by 2.6% during the 2nd quarter. Capstone Asset Management Co. now owns 6,755 shares of the company’s stock worth $392,000 after acquiring an additional 170 shares during the period. Finally, M&T Bank Corp grew its holdings in shares of Alkermes PLC by 2.9% during the 2nd quarter. M&T Bank Corp now owns 7,135 shares of the company’s stock worth $413,000 after acquiring an additional 200 shares during the period. 98.51% of the stock is owned by institutional investors.
Several analysts recently weighed in on ALKS shares. ValuEngine downgraded Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Zacks Investment Research upgraded Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. BidaskClub downgraded Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Jefferies Group LLC set a $69.00 target price on Alkermes PLC and gave the company a “buy” rating in a research report on Friday, August 25th. Finally, Barclays PLC downgraded Alkermes PLC from an “overweight” rating to a “hold” rating in a research report on Monday. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the stock. Alkermes PLC currently has a consensus rating of “Hold” and an average price target of $64.13.
Alkermes PLC Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with our FREE daily email newsletter.